-
公开(公告)号:US07407772B2
公开(公告)日:2008-08-05
申请号:US10490462
申请日:2002-09-20
IPC分类号: C12Q1/48
CPC分类号: C12Q1/48 , A61K31/19 , A61K31/366 , A61K31/40 , G01N2333/90245 , G01N2333/91245 , G01N2500/04 , A61K2300/00
摘要: A method for screening statins in their open acid form to determine the susceptibility of each tested statin to metabolic glucuronidation is provided. Also provided is a method for determining if a non-statin pharmaceutical drug co-administered with a statin that is susceptible to metabolic glucuronidation in its open acid form, will inhibit the glucuronidation of the statin and thereby increase the risk of an adverse drug interaction.
摘要翻译: 提供了以开放酸形式筛选他汀类药物以确定每种被测他汀类药物对代谢葡萄糖醛酸化的敏感性的方法。 还提供了一种用于确定与其开放酸形式易于代谢葡糖醛酸化的他汀类药物共同施用的非他汀类药物是否将抑制他汀类药物葡糖醛酸化,从而增加不良药物相互作用的风险的方法。
-
公开(公告)号:US06426353B1
公开(公告)日:2002-07-30
申请号:US09952084
申请日:2001-09-14
申请人: Byron H. Arison , Donghui Cui , Mark E. Duggan , Wasyl Halczenko , John H. Hutchinson , Thomayant Prueksaritanont , Raju Subramanian , Xiaojun Fang
发明人: Byron H. Arison , Donghui Cui , Mark E. Duggan , Wasyl Halczenko , John H. Hutchinson , Thomayant Prueksaritanont , Raju Subramanian , Xiaojun Fang
IPC分类号: A61K31435
CPC分类号: C07D471/04
摘要: The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as &agr;v&bgr;3 integrin receptor antagonists. The compounds of the present invention are useful for inhibiting bone resorption, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammatory arthritis, cancer, and metastatic tumor growth. They are particularly useful for inhibiting bone resorption and for the treatment and prevention of osteoporosis.
摘要翻译: 本发明涉及由结构式(1)的化合物,含有这些化合物的药物组合物的代谢转化形成的新化合物,以及它们作为α-角蛋白3整联蛋白受体拮抗剂的用途。 本发明的化合物可用于抑制骨吸收,再狭窄,血管生成,糖尿病性视网膜病变,黄斑变性,炎症性关节炎,癌症和转移性肿瘤生长。 它们对抑制骨吸收和治疗和预防骨质疏松症尤其有用。
-